This excerpt taken from the EYE 8-K filed Oct 31, 2008.
Refractive sales declined 14.4% to $96.0 million.
Procedures, implants and related sales declined 11.3% to $67.2 million, as growth in Japan and Asia Pacific was unable to offset significant declines in the U.S.
and Europe.
AMOs U.S. excimer procedure volumes declined approximately 35% in the third quarter and approximately 17% for the trailing 12 months ended September 26,
2008; the companys U.S. custom mix was 69.5% in the third quarter and 67.6% for the trailing 12 months ended September 26, 2008.
AMOs U.S. femtosecond procedure volumes declined approximately 12% in the third quarter and rose approximately 14% for the trailing 12 months ended
September 26, 2008, on a pro forma basis.
AMOs international procedure, implant and related sales were $31.7 million, up 33.1%, reflecting strong growth in Japan and Asia Pacific.
System sales declined 31.2% to $18.8 million, reflecting a sharp pullback in new equipment purchases by LASIK providers on a global basis.
Bet you've never seen portfolio analytics like these.